Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2004, p. 4441-4443, Vol. 48, No. 11
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.11.4441-4443.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
College of Pharmacy, University of New Mexico, Albuquerque, New Mexico
Received 20 April 2004/ Returned for modification 8 June 2004/ Accepted 20 July 2004
|
|
|---|
|
|
|---|
(This work was previously presented in part [Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 121, 2003].)
Fifteen unique clinical C. glabrata bloodstream isolates obtained from TriCore Reference Laboratories (Albuquerque, N.Mex.) and two quality control isolates, ATCC 6258 (C. krusei) and ATCC 22019 (C. parapsilosis), were tested. Fluconazole and itraconazole powder were obtained through Sigma Chemicals (St. Louis, Mo.). Pfizer, Inc. (New York, N.Y.) donated the voriconazole powder used in this study. Drug stock solutions (100x) were prepared as outlined by the NCCLS M27-A2 document and stored frozen at 80°C until plate preparation. Etest strips of fluconazole, itraconazole, and voriconazole were purchased through AB Biodisk North America (Piscataway, N.J.). Alamar Blue 100x was purchased through Trek Diagnostics Inc. (Cleveland, Ohio) to perform susceptibility testing by the SYO method. Isolates were tested against all antifungal agents with 0.075 M 3-(N-morpholino)propanesulfonic acid (MOPS)-buffered RPMI 1640 medium supplemented with dextrose to 20 g/liter and adjusted to pHs 7.0, 6.0, and 7.4. Microplates containing appropriate drug dilutions were sealed, stored frozen at 80°C, and thawed prior to each experiment. MICs were interpreted in duplicate at 24 and 48 h after incubation at 35°C both visually and by the use of a spectrophotometer reading at 490 nm as previously described (7).
Triazole MIC determinations were also performed in duplicate by the SYO method that included incorporation of Alamar Blue 100x to a final concentration of 1% (vol/vol) per well. MICs were interpreted as the lowest antifungal concentration that corresponded to the first purple or blue well after 24 h of incubation at 35°C (1). The Etest procedure included preparation of agar plates with MOPS-buffered RPMI 1640 medium-2% dextrose adjusted to the specified pH, Bacto Agar (1.5 g/dl), and previously described experimental procedures (2). Etest triazole results include a wide array of elliptical profiles and trailing growth that required interpretation based on Etest photographically illustrated technical guideline 4 (AB Biodisk NA, Piscataway, N.J.).
Tables 1, 2, and 3 include the specific MICs generated by the NCCLS M27-A2 (48 h), SYO (24 h), and Etest (48 h) methods at the three pH values used against fluconazole, itraconazole, and voriconazole, respectively. In general, the MICs of 2 of the 15 C. glabrata isolates and both ATCC strains were unaffected by the alterations in pH. These two clinical isolates included a highly susceptible strain (Z-zAN) and a highly resistant strain (Z-zAS) that demonstrated essentially identical MIC profiles at the three pH values and by all of the susceptibility test methods used. The two quality control American Type Culture Collection strains were not affected by pH. The MICs were more easily interpretable at pH 6.0 compared to either pH 7.0 or 7.4. The 48-h MICs generated by the NCCLS M27-A2 method with a spectrophotometric endpoint was identical to the visual endpoint for >90% of the isolates tested at all three pH values. Figure 1 illustrates the optical density profile of a C. glabrata isolate tested by the NCCLS M27-A2 method. The graph demonstrates the higher MIC but sharper and correspondingly easier to visually interpret endpoint seen at pH 6.0. Assessment of MICs by the Etest method demonstrated reduction in triazole MICs with incremental pH increases (Fig. 2).
|
View this table: [in a new window] |
TABLE 1. Comparison of fluconazole MICs against C. glabrata isolates by the NCCLS M27-A2 (48 h), Sensititre YeastOne (24 h), and Etest (48 h) methods at different pHs
|
|
View this table: [in a new window] |
TABLE 2. Comparison of itraconazole MICs against C. glabrata isolates by the NCCLS M27-A2 (48 h), Sensititre YeastOne (24 h), and Etest (48 h) methods at different pHs
|
|
View this table: [in a new window] |
TABLE 3. Comparison of voriconazole MICs against C. glabrata isolates by the NCCLS M27-A2 (48 h), Sensititre YeastOne (24 h), and Etest (48 h) methods at different pHs
|
![]() View larger version (16K): [in a new window] |
FIG. 1. Optical density (OD) of microwells at 48 h of fluconazole exposure at the specified pH values against C. glabrata (isolate R).
|
![]() View larger version (126K): [in a new window] |
FIG. 2. Forty-eight-hour triazole Etest results of C. glabrata (isolate Z-zAD). Panels: A, key; B, fluconazole; C, itraconazole; D, voriconazole.
|
8 µg/ml) was different: 6.6% at pH 6.0, 40% at pH 7.0, and 66% at pH 7.4. Itraconazole MICs at pH 7.4 were significantly lower than those at pH 7.0 by all three susceptibility-testing methods (P < 0.02). However, the MICs at pH 6.0 were not significantly higher than those at pH 7.0. Most of the isolates were resistant to itraconazole at pH 7.0, but 38% of them were susceptible (
0.125 µg/ml) and 38% were dose-dependently susceptible (0.25 to 0.5 µg/ml) at pH 7.4 by the NCCLS M27-A2 method. Reduction of the pH to 6.0 was associated with significantly higher voriconazole MICs (2 doubling dilutions higher) by both the NCCLS M27-A2 and SYO methods (P < 0.001) but not by the Etest method (P > 0.05). These MICs at pH 7.4 were significantly lower than those at pH 7.0 by approximately 2 dilutions by all three susceptibility-testing methods (P < 0.001). The percentages of isolates classified as voriconazole susceptible (
1 µg/ml) were different: 47% at pH 6.0, 80% at pH 7.0, and 93% at pH 7.4. As demonstrated in the present study, the NCCLS M27-A2 method with media buffered to pH 7.0 did not consistently predict the activity of triazoles against C. glabrata at urine and blood pH values. The susceptibility profiles of fluconazole, itraconazole, and voriconazole were markedly improved at pH 7.4 compared to those at pH 7.0 when C. glabrata was tested. The two commercially available susceptibility-testing methods produced similar results. Further investigations assessing the clinical utility of antifungal susceptibility testing should take these findings into consideration.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»